The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Eli Lilly is flagged in Yahoo Finance screen of “longevity” and “anti-aging” stocks
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 22, 9:22 AM EDT

Eli Lilly is flagged in Yahoo Finance screen of “longevity” and “anti-aging” stocks

A Yahoo Finance roundup ranks Eli Lilly and Company’s LLY shares among stocks it describes as aligned with longevity and anti-aging themes, pointing to a relatively low short position in the stock and grouping it with other companies working in the broader healthspan space.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly and Company (NYSE:LLY) is being highlighted in a Yahoo Finance market roundup that asks whether selected companies could be viewed as “longevity” and “anti-aging” plays. The article, published June 22, frames the screening process around theme-aligned research focus and market positioning, placing LLY among seven stocks it labels as the “best” in that category.

The post says the screening identified a “short percentage of shares outstanding” of 1.10% for Eli Lilly, describing that as a factor in its selection. In basic terms, a short percentage of shares outstanding reflects the portion of a company’s shares that investors have sold short, typically interpreted as a measure of how aggressively the market is betting against the stock.

Beyond the Eli Lilly mention, the roundup also references another company, Austin-based 4E Therapeutics, noting activity dated June 16. However, the Yahoo Finance item does not provide additional detail in the materials available here about that company’s specific pipeline, trial results, or any direct linkage to Eli Lilly’s work.

The article’s central contribution is therefore not a new clinical or commercial development from Eli Lilly, but a themed investor pitch. It treats longevity and anti-aging as an investment lens and uses stock-level positioning metrics to argue that some companies in the category may be relatively better positioned from a market sentiment standpoint than others.

Still, investors should treat such screens as starting points rather than conclusions. Market roundups can blend qualitative theme labels with quantitative metrics, and theme-focused investing can include companies at very different stages of drug development, regulatory progress, and commercial scale.

For Eli Lilly, the key takeaway from the roundup is that the market narrative around “longevity” and “anti-aging” remains active even without the article disclosing any new Lilly-specific catalysts such as trial readouts, regulatory actions, or near-term product launches. The post, as provided here, does not cite a particular Eli Lilly program or publication tied to aging biology.

It is also unclear, based on the available text, how the article defines its longevity and anti-aging universe, what data sources it uses for the screening, and how it weights short positioning versus company fundamentals. Without those details, readers are left with the article’s framing rather than a transparent methodology.

What to watch next is whether Eli Lilly’s longevity-adjacent narrative is supported by concrete milestones. That could include trial updates in aging-related indications, pipeline disclosures tied to healthspan biology, or further investor communication clarifying which programs the company views as most relevant to the longevity market theme.

Why It Matters

  • Theme-based stock lists can influence near-term investor attention even when no new company-specific catalysts are reported.
  • Short-position metrics such as “short percentage of shares outstanding” are often used as a proxy for market sentiment, but they do not, by themselves, indicate scientific or commercial success.
  • Longevity and anti-aging remain active areas for capital allocation, which can affect how investors interpret otherwise standard biotech and pharma updates.
  • Because the screen’s methodology and included criteria are not fully disclosed in the available text, the list should be treated as a prompt for deeper review rather than evidence of performance.

Sources

Key Facts

  • Eli Lilly and Company (NYSE:LLY) was included in a Yahoo Finance roundup of “longevity” and “anti-aging” stocks.
  • The Yahoo Finance post says LLY’s “short percentage of shares outstanding” is 1.10%.
  • The article was published June 22, 2026.
  • The roundup references an Austin-based neuroscience company, 4E Therapeutics, and mentions an item dated June 16.
  • The available materials do not describe any specific new Eli Lilly clinical results or regulatory actions.

Healthcare Related